Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning

Vittorio Martinelli; Bruno Colombo; Gloria Dalla Costa; Dacia Dalla Libera; Lucia Moiola; Andrea Falini; Gıancarlo Comı; Massimo Filippi

doi:10.1177/1352458513492246

Related publications

Article2022

Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years

Emilio Portaccio, Luisa Pastò, Lorenzo Razzolini, Lucia Moiola, Vittorio Martinelli, Pietro Annovazzi, Angelo Ghezzi, Mauro Zaffaroni, Roberta Lanzillo, Vincenzo Brescia Morra, Francesca Rinaldi, Paolo Gallo, Claudio Gasperini, Damiano Paolicelli, Marta Simone, Carlo Pozzilli, Laura De Giglio, Paola Cavalla, Eleonora Cocco, Maria Giovanna Marrosu, Francesco Patti, Claudio Solaro, Giancarlo Comi, Massimo Filippi, María Trojano, Maria Pia Amato

Article2024

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis

Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, Damiano Paolicelli, Emilio Portaccio, Matilde Inglese, Matteo Foschi, Francesco Patti, Franco Granella, Silvia Romano, Paola Cavalla, Giovanna De Luca, Paolo Gallo, Paolo Bellantonio, Antonio Gallo, Sara Montepietra, Alessia Di Sapio, Marika Vianello, R. Quatrale, Daniele Spitaleri, Raffaella Clerici, Valentina Torri Clerici, Eleonora Cocco, Vincenzo Brescia Morra, ,

Article2010

Safety and efficacy of natalizumab in children with multiple sclerosis

Angelo Ghezzi, Carlo Pozzilli, Luigi Grimaldi, Vincenzo Brescia Morra, F. Bortolon, Ruggero Capra, Massimo Filippi, Lucia Moiola, Maria A. Rocca, Mariarosa Rottoli, Paola Sarchielli, Mauro Zaffaroni, Gıancarlo Comı

Article2013

Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases

Angelo Ghezzi, Carlo Pozzilli, LME. Grimaldi, Lucia Moiola, Vincenzo Brescia Morra, Alessandra Lugaresi, Giacomo Lus, Francesca Rinaldi, Maria A. Rocca, María Trojano, Antonio Bianchi, Giancarlo Comi, Massimo Filippi

Article2017

Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study

Stephanie Licata, Helmut Butzkueven, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Q. Dong, Nolan Campbell, Pei‐Ran Ho